Keywords: Alzheimers and Myelin
We have been looking in the wrong place.
For thirty years, the dominant theory of Alzheimer’s disease has pointed at amyloid plaques: the sticky protein deposits that accumulate between neurons in the brains of people with the condition. The theory is straightforward. The plaques build up. They disrupt neural communication. The brain degrades. The self dissolves. And so the pharmaceutical industry has spent billions of dollars and several decades developing drugs that clear amyloid from the brain.
The treatments have not worked. Or rather, they have done exactly what they promised, they have reduced amyloid burden in the brain, and the patients have continued to deteriorate anyway. The plaques were cleared. The disease continued. Something else is driving this.
It is worth sitting with that for a moment. Not as a criticism of the researchers involved, many of whom are brilliant and dedicated people, but as a simple observation about what the evidence is telling us. If removing the suspected cause does not stop the disease, then perhaps the suspected cause was never the cause. Perhaps it was always the consequence.
The brain’s immune system
The brain is a protected environment. The blood brain barrier, a dense layer of specialised cells lining the brain’s blood vessels, controls what enters and what stays out. Most of the body’s immune apparatus operates on the other side of that barrier. Inside it, the immune function of the brain belongs almost entirely to a class of glial cells called microglia.
Microglia are the brain’s resident immune cells. They are small, mobile, and extraordinarily active. Under healthy conditions they extend fine processes into the spaces between cells, sampling the environment, checking for damage, pathogens, or debris, and retracting. They are the sentinels of the brain’s interior, and under normal circumstances they are very good at their job. They distinguish reliably between self and other, between the brain’s own tissue and anything that doesn’t belong there.
R. Douglas Fields, in his account of the brain’s glial systems, describes the intimacy of the microglial relationship with the neural environment. These cells are not patrolling from a distance. They extend their processes into the tightest spaces in the brain, including, it appears, the paranodal regions at the nodes of Ranvier, the brief exposed gaps in the myelin sheath where the axon is uninsulated and metabolically active. If an astrocyte can extend a process into that tight periaxonal space to shuttle lactate to a working axon, there is no obvious reason why a microglia cannot extend a process into the same space to sample what is there.
This is worth noting because it resolves a question about how an immune attack on myelin could preferentially target recently myelinated sheaths. The outer layers of compact myelin, laid down earliest, consolidated over decades into something approaching the density of scar tissue, may present a paranodal architecture that the microglia have long since categorised as self. The recently myelinated sheath, still consolidating, still remodelling its paranodal junctions, still expressing surface proteins associated with active construction, may present a different signature. Not foreign exactly. But not fully familiar either. Something in between, which is precisely the kind of ambiguity that a dysregulated immune system resolves in the worst possible way.
What amyloid might actually be
Here is a possibility worth considering, stated carefully and without more confidence than the evidence warrants.
What if amyloid is not the cause of Alzheimer’s disease, but the residue of it? What if the plaques that have absorbed so much research attention are not the fire but the ash?
Myelin is approximately seventy percent lipid. It is one of the most lipid-rich substances in the body. When myelin is broken down, the debris has to go somewhere. The microglia, having attacked the sheath, must process what they have consumed. The byproducts of that processing, including misfolded proteins generated during the degradation of myelin components, accumulate in the space between cells.
This would explain something that has always been slightly awkward about the amyloid hypothesis: the plaques appear to correlate with disease progression, but they do not map cleanly onto cognitive symptoms. Some people have significant amyloid burden and relatively intact cognition. Others show severe cognitive decline with modest plaque accumulation. If amyloid were the primary driver of neurodegeneration, this variability would be difficult to explain. If amyloid is a downstream marker of microglial activity, the variability makes more sense. What matters is not how much debris has accumulated, but how active the underlying process is, and where in the brain it is currently operating.
The pharmaceutical trials that cleared amyloid and saw no cognitive benefit may have been doing something analogous to cleaning the floors of a burning building. The floors were cleaner. The building was still on fire.
What starts the fire
If the microglia are the mechanism, the more important question is what dysregulates them. What turns a functioning immune system into one that attacks the brain’s own white matter?
The gut-brain axis research of the past decade offers some uncomfortable suggestions. The gut wall, like the blood brain barrier, is a selective membrane. When it is healthy, it admits nutrients and excludes pathogens. When it is compromised, by chronic inflammation, by dietary factors, by the long-term consequences of modern processed food, things cross that should not. Bacterial lipopolysaccharides, partially digested proteins, inflammatory cytokines: these enter the bloodstream and create a systemic inflammatory environment. That environment does not stay outside the brain indefinitely. Chronic systemic inflammation is one of the known risk factors for blood brain barrier compromise. And a compromised blood brain barrier is a brain whose microglia are suddenly exposed to molecules they were never trained to tolerate.
The molecular mimicry mechanism is well established in autoimmune conditions elsewhere in the body. The thyroid is a clear example. Gluten proteins, when they cross a compromised gut wall and enter the bloodstream, can present a molecular profile that resembles thyroid hormone closely enough to trigger an immune response. The immune system, trained on the intruder, begins attacking the thyroid itself. The thyroid did not change. The immune system learned the wrong lesson.
It is not unreasonable to ask whether something similar might occur in the brain. Whether molecules crossing a compromised blood brain barrier might present profiles that resemble myelin surface proteins closely enough to train microglia into misidentification. Whether the chronic low-grade neuroinflammation that precedes Alzheimer’s symptoms by years might represent the immune system learning, slowly and catastrophically, to see white matter as a pathogen.
This is speculation. It should be understood as such. But it is speculation grounded in established mechanisms, and it points toward a research programme that is notably different from the one that has dominated the field.
A question about statins
There is one more observation to place on the table, offered not as accusation but as a question that seems not to be asked loudly enough.
Myelin is approximately seventy percent lipid. This is not a minor biochemical detail. The brain is the most lipid-rich organ in the body, and a very large proportion of that lipid is structural: it is the myelin sheath. The maintenance of myelin throughout adult life requires a continuous supply of lipid. Oligodendrocytes are not passive structures. They are actively repairing, remodelling and extending sheaths throughout the lifespan. That work requires raw material.
Statins are lipid-lowering drugs. They are among the most widely prescribed medications in the world, and they are prescribed with particular frequency to older adults, including, in many cases, residents of aged care facilities who receive them as a matter of routine rather than individual clinical assessment.
Whether statins cross the blood brain barrier is a contested question. The lipophilic statins, those that dissolve in fat rather than water, are more likely to cross than the hydrophilic ones. The research is not conclusive. No pharmaceutical manufacturer can state with certainty that their statin does not cross the barrier in meaningful concentrations. The studies that would answer the question definitively have not been done at the scale and duration that chronic administration to elderly populations would require.
If a lipid-lowering drug crosses the blood brain barrier and reduces lipid availability in the brain environment, it is worth asking what effect that reduction has on myelin maintenance. Not dramatically, not acutely, but chronically, over years of daily administration to an ageing brain whose myelin maintenance capacity is already declining. Whether sheaths that are inadequately maintained might present the kind of irregular paranodal architecture that a vigilant immune system could misread. Whether the population most aggressively prescribed these drugs is the same population in which Alzheimer’s rates are highest not merely because both conditions share the risk factor of age, but because one may be contributing to the conditions in which the other develops.
This is not a conclusion. It is a question. The evidence does not currently support a stronger claim than that.
But it is the kind of question that, once asked, is difficult to unask.
What the Myelin Mind sees
The standard account of Alzheimer’s is a story about memory. She forgot who I was. He couldn’t remember the names of his grandchildren. The self, in this account, is identified with memory, and Alzheimer’s is the disease that takes memory away.
The Myelin Mind account is different, and in some ways harder to bear.
If the self is not a memory system but a myelinated structure, if who we are is the accumulated condition of everything we have experienced, inscribed into white matter over a lifetime, then Alzheimer’s is not a disease of forgetting. It is a disease of unbecoming. The self is not losing access to its contents. It is losing its structure. The myelinated condition that constitutes a person, the pathways that carry their habits, their relationships, their language, their knowledge of how to move through the world, is being systematically dismantled.
The sequence matters. In the early stages, the most recently myelinated structures are the most affected. Recent memories, newly acquired skills, the latest layers of a life. The person becomes, in a precise sense, an earlier version of themselves. The grandchildren they cannot name were not there when the deepest pathways were laid. The spouse of fifty years was. The music of their youth was. The feel of a familiar object in the hand was. These persist not because memory is selective in its failures, but because the white matter that carries them is older, more consolidated, harder for the microglia to reach.
In the later stages the discrimination fails. The attack spreads into structures that have been myelinated since childhood, since infancy, since before birth. The ability to walk. The ability to swallow. Eventually the autonomic functions that keep the body alive. This is not an orderly retreat to a primitive self. It is the progressive destruction of the biological substrate of selfhood, until there is nothing left to sustain.
What we are watching, in a person with late-stage Alzheimer’s, is not a mind that has forgotten. It is a mind that is being taken apart, from the outside in, at the level of its physical structure.
The amyloid plaque is what remains when the structure is gone. It is not the cause of the taking apart. It is the debris.
Jack Parry is a philosopher, polyglot and biomedical animator at Swinburne University of Technology. He is the author of The Myelin Mind: The Genesis of Meaning.